Avantor acquires RFCL
Avantor, a US-based manufacturer of chemistries and materials used in
biotechnology and pharmaceutical production, has acquired Indian firm
RFCL from ICICI Venture. Avantor, previously known as Mallinckrodt
Baker, was acquired by an affiliate of New Mountain Capital, in August
2010. Avantor and its subsidiaries, manufacture and market
high-performance chemistries and materials globally, under two
well-known and respected brand names, JT Baker and Mallinckrodt
Headquartered in New Delhi, RFCL is a leader in laboratory reagents and
consumables, as well as products for the medical diagnostics market in
India. Through its Rankem division, RFCL offers over 20,000 different
laboratory products to over 5,000 customers across a variety of
industries including pharmaceuticals, biotechnology, research
organizations and educational institutions. RFCL’s Diagnova division
offers approximately 2,000 products used by over 6,000 customers;
primarily in Indian in vitro diagnostics, medical devices and life
science research markets, which cater to hospitals, pathology
laboratories and blood banks.
Avantor identified RFCL as an attractive target to build on its current
presence in the laboratory and pharmaceutical markets in India.
Agilent, Wyss in technology deal
Agilent Technologies and Wyss Institute for Biologically Inspired
Engineering at Harvard University, US, have reached an agreement to
work together to develop innovative tools, technologies and instruments
that will advance human health and improve the environment.
Under the multi-year agreement, Agilent will provide financial support,
unique tools and materials to support Wyss’ biomaterials evolution,
programmable nanomaterials and biomimetic microsystems platforms.
Agilent will also contribute its technical expertise to the
Through its collaboration with pioneers in the fields of synthetic
biology and programmable nanomaterials at the Wyss Institute, Agilent
aims to identify new high-value applications and challenges, as well as
to advance its already powerful technological capabilities in genome
engineering and nanobiotechnology.
In the emerging field of mechanobiology, this collaboration will
develop new integrated force analysis and imaging capabilities that
combine advanced optics and nanomechanical measurements. The goal is to
provide deeper insights into the way physical forces and the mechanical
properties of living tissues influence cell behavior, and contribute to
the onset and progression of diseases such as cancer.